BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Biomed Pharmacother 2019;114:108864. [PMID: 30981107 DOI: 10.1016/j.biopha.2019.108864] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 2020;11:902. [PMID: 33097691 DOI: 10.1038/s41419-020-03123-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
3 Marin JJG, Macias RIR, Monte MJ, Romero MR, Asensio M, Sanchez-Martin A, Cives-Losada C, Temprano AG, Espinosa-Escudero R, Reviejo M, Bohorquez LH, Briz O. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1663. [PMID: 32585893 DOI: 10.3390/cancers12061663] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
4 Duan B, Huang C, Bai J, Zhang YL, Wang X, Yang J, Li J; Department of Medical Oncology, Shaanxi Provincial People’s Hospital, China, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi’an Jiaotong University, China, Department of Medical Oncology, Shaanxi Provincial People’s Hospital, China, Department of Neurology, Shaanxi Provincial People’s Hospital, China, Department of Medical Oncology, Shaanxi Provincial People’s Hospital, China, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi’an Jiaotong University, China, Department of National & Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, the Second Affiliated Hospital, Xi’an Jiaotong University, China. Multidrug Resistance in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 141-58. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines (Basel) 2020;8:E41. [PMID: 31991677 DOI: 10.3390/vaccines8010041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
7 Wang Y, Liu S, Chen Q, Ren Y, Li Z, Cao S. Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell proliferation. Life Sci 2021;277:119521. [PMID: 33891940 DOI: 10.1016/j.lfs.2021.119521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Jurgelewicz A, Dornbos P, Warren M, Nault R, Arkatkar A, Lin H, Threadgill DW, Zacharewski T, LaPres JJ. Genetics-Based Approach to Identify Novel Genes Regulated by the Aryl Hydrocarbon Receptor in Mouse Liver. Toxicol Sci 2021;181:285-94. [PMID: 33720361 DOI: 10.1093/toxsci/kfab032] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
10 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li S, Shen L. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. J Cancer 2020;11:5056-68. [PMID: 32742453 DOI: 10.7150/jca.44408] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]